Custom made generation of recombinant P53
Ended Purchase Order Awarded Last action
- Contract number
- 75N91024P00734
- Awardee
-
Dapcel Inc. UEI HXX7K55XCKZ9
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $18,000
Award facts
- Contract value 100% obligated
- $18,000.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 325414 Biological Product (except Diagnostic) Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Competed under SAP · 2 offers Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- Bethesda, MD 20892, USA
Award details come from SAM.gov/FPDS.
About this award
The National Cancer Institute (NCI), a civilian federal agency, awarded a firm-fixed-price purchase order contract to Dapcel Inc., a woman-owned business, for the custom generation of recombinant p53 at a ceiling value of $18,000.00. The contract has an ultimate completion date of September 19, 2025. This contract award does not have a set-aside designation.
Quick answers
Who was awarded contract 75N91024P00734?
75N91024P00734 was awarded to Dapcel Inc. by National Cancer Institute (National Institutes of Health) on September 20, 2024.
How much is contract 75N91024P00734 worth?
The government has obligated $18,000 on 75N91024P00734.
Was contract 75N91024P00734 competed?
The extent of competition for 75N91024P00734 was competed under sap. The government received 2 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award